Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial

@article{Bishop2013RisedronateIC,
  title={Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial},
  author={Nicholas Bishop and Silvano Adami and S. Faisal Ahmed and Jordi Ant{\'o}n and Paul Arundel and Christine P. Burren and J. P. Devogelaer and Thomas N. Hangartner and {\'E}va Hossz{\'u} and Joseph Michael Lane and Roman S. Lorenc and Outi M{\"a}kitie and Craig F Munns and Ana Paredes and Helene Pavlov and Horacio Plotkin and Cathleen L. Raggio and Mar{\'i}a Loreto Reyes and Eckhard Schoenau and Oliver Semler and David O. Sillence and Robert D. Steiner},
  journal={The Lancet},
  year={2013},
  volume={382},
  pages={1424-1432}
}
BACKGROUND Children with osteogenesis imperfecta are often treated with intravenous bisphosphonates. We aimed to assess the safety and efficacy of risedronate, an orally administered third-generation bisphosphonate, in children with the disease. METHODS In this multicentre, randomised, parallel, double-blind, placebo-controlled trial, children aged 4-15 years with osteogenesis imperfecta and increased fracture risk were randomly assigned by telephone randomisation system in a 2:1 ratio to… Expand
A randomized, double blind, placebo-controlled trial of alendronate treatment for fibrous dysplasia of bone.
TLDR
Alendronate treatment led to a reduction in the bone resorption marker NTX-telopeptides, and improvement in aBMD, but no significant effect on serum osteocalcin, pain, or functional parameters. Expand
The prevention and treatment of glucocorticoid-induced osteopaenia in juvenile rheumatic disease: A randomised double-blind controlled trial☆
TLDR
Children and adolescents receiving steroids for rheumatic diseases benefit from prophylactic treatment with bisphosphonates to increase LSaBMD, but not between the alfacalcidol and risedronate groups. Expand
Safety and efficacy of denosumab in children with osteogenesis imperfecta - a first prospective trial
TLDR
On average, there was a significant increase in lumbar spine aBMD percent change after 48 weeks of denosumab, and further trials are necessary to assess long-term side effects and efficacy. Expand
Efficacy and Safety of Bisphosphonate Therapy in Children with Osteogenesis Imperfecta: A Systematic Review
TLDR
Treatment with oral or intravenous BPs in children with OI results in an increase in bone mineral density and seems to be safe and well tolerated. Expand
Evaluation of teriparatide treatment in adults with osteogenesis imperfecta.
TLDR
Osteoporosis Imperfecta patients with OI, particularly those with less severe disease (type I), displayed a teriparatide-induced anabolic response, as well as increased hip and spine aBMD, vertebral v BMD, and estimated vertebral strength. Expand
Do Bisphosphonates Alleviate Pain in Children? A Systematic Review
TLDR
Intravenous BPs are helpful in alleviating bone pain in children and adolescents but the heterogeneity of the doses used, duration of treatments, and types of pathologies included shows the paucity of high-quality evidence in the available literature and further research is needed. Expand
EFFECTS OF LONG-TERM ALENDRONATE TREATMENT ON A LARGE SAMPLE OF PEDIATRIC PATIENTS WITH OSTEOGENESIS IMPERFECTA.
  • F. Lv, Y. Liu, +8 authors Mei Li
  • Medicine
  • Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • 2016
TLDR
Three years' treatment with alendronate was demonstrated for the first time to significantly reduce fracture incidence, increase lumbar spine and femoral neck BMD, and decrease bone turnover biomarkers in Chinese children and adolescents with OI. Expand
Bisphosphonates for the Prevention of Fractures in Osteogenesis Imperfecta: Meta‐Analysis of Placebo‐Controlled Trials
TLDR
The effects of bisphosphonates on fracture prevention in osteogenesis imperfecta are inconclusive and adequately powered trials with a fracture endpoint are needed to further investigate the risks and benefits of bis phosphonate in this condition. Expand
Bisphosphonate Treatment and the Characteristics of Femoral Fractures in Children With Osteogenesis Imperfecta
TLDR
Characteristics of femoral fractures in children with OI are affected by OI type but not by BP exposure, and distal location and transverse configuration were more common in the more severe types III and IV compared with type I OI. Expand
Acute and long-term effects of zoledronate in adult patients with osteogenesis imperfecta. An observational Spanish study with five years of follow-up
TLDR
Zoledronic acid is a convenient, safe, and effective treatment that increases BMD in adult patients with OI and the safety of this treatment is confirmed. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 38 REFERENCES
Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study.
TLDR
Oral ALN for 2 yr in pediatric patients with OI significantly decreased bone turnover and increased spine areal BMD but was not associated with improved fracture outcomes. Expand
A randomized, controlled dose‐ranging study of risedronate in children with moderate and severe osteogenesis imperfecta
  • N. Bishop, R. Harrison, +9 authors A. Rigby
  • Medicine
  • Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
  • 2010
TLDR
The most appropriate dose of risedronate for children with moderate to severe osteogenesis imperfecta in this study was 2 mg/kg per week, and bone mass increased and bowing deformities reduced with increasing risingronate dose. Expand
Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study
TLDR
Oral treatment with olpadronate at a daily dose of 10 mg/m2 results in a reduction of fracture risk of long bones in children with osteogenesis imperfecta, and the issue of whether bisphosphonates will alter the natural course of osteogenesisperfecta remains unresolved, and further studies are needed. Expand
Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta.
TLDR
The data support that intravenous pamidronate therapy is safe, increases BMD, and reduces fracture rates in very young children with OI and would seem to be the best available treatment for these children. Expand
Cyclic administration of pamidronate in children with severe osteogenesis imperfecta.
TLDR
In children with severe osteogenesis imperfecta, cyclic administration of intravenous pamidronate improved clinical outcomes, reduced bone resorption, and increased bone density. Expand
Intravenous pamidronate treatment of infants with severe osteogenesis imperfecta
TLDR
APD is an efficient symptomatic treatment for infants with severe osteogenesis imperfecta, but additional orthopaedic surgery is often needed, and long-term follow-up is important. Expand
Two doses of pamidronate in infants with osteogenesis imperfecta
TLDR
Pamidronate dose in infants may influence lumbar spine bone acquisition and improve vertebral size after prior crush fracturing and did not over-suppress bone turnover. Expand
Impact of Alendronate on Quality of Life in Children With Osteogenesis Imperfecta
TLDR
Daily alendronate therapy is safe and effective in improving QOL in children with OI and vertebral bone mineral density improved after 1 year of alendronsate therapy. Expand
Bisphosphonate therapy for osteogenesis imperfecta.
TLDR
Osteogenesis imperfecta is caused by a genetic defect resulting in an abnormal type I collagen bone matrix which typically results in multiple fractures with little or no trauma, and oral or intravenous bisphosphonates increase bone mineral density in children and adults with this condition. Expand
Beneficial effect of bisphosphonate during five years of treatment of severe osteogenesis imperfecta
TLDR
It is indicated that APD is of value in the symptomatic treatment of children with severe OI and a major improvement in well‐being, pain and activities of daily life is reported. Expand
...
1
2
3
4
...